ACG's Major Investment in U.S. Manufacturing
ACG is set to make a substantial $200 million investment aimed at establishing its first manufacturing operations for empty capsules in the United States. This phased investment will significantly reinforce ACG's presence in North America and aims to further align with customer needs.
Boosting Employment and Local Economy
The initial phase of this investment involves a commitment of $100 million to develop a state-of-the-art hard-shell capsule facility in Atlanta. This strategic move is anticipated to create over 200 jobs and provide valuable contributions to the local economy. ACG is not just investing in infrastructure but also in the community, aiming for operational commencement in early 2027.
Enhanced Manufacturing Capabilities
In addition to the initial investment, a second phase of another $100 million is planned to enhance the manufacturing capabilities and expand overall capacity within the region. This move illustrates ACG's dedication to meeting the growing demands for high-quality solid-dosage solutions.
Commitment to Quality and Innovation
As Karan Singh, Managing Director of ACG, stated, "This facility strengthens our ties with customers across the region—bringing us closer to them, enabling faster lead times, higher-quality service, and a more resilient supply chain." This new facility represents a culmination of years of planning and reflects ACG's commitment to innovation and excellence.
ACG's new operations will focus on manufacturing both gelatin and vegetarian (HPMC) hard-shell capsules, adhering to the highest global standards of quality and safety. This commitment aligns with ACG's mission to push boundaries in the pharmaceutical and nutraceutical fields.
Strategic Location Advantages
Selwyn Noronha, CEO of ACG Capsules, emphasized the strategic importance of Atlanta as a hub for large-scale operations. He noted that the city's pro-business environment fosters growth and development, making it an ideal choice for ACG's expansion.
Global Integration and Future Growth
ACG has established a robust model over its 25 years of service in North America, with a network that includes manufacturing locations and warehousing spread across the country. This new investment will enhance ACG's operational efficiency and customer responsiveness.
About ACG
For over 65 years, ACG has been at the forefront of production solutions for pharmaceutical and nutraceutical companies. As a leading provider of oral-dosage products and services, ACG manufactures capsules, barrier packaging materials, and machinery that adhere to strict international quality standards. With partnerships spanning 138 countries, ACG is dedicated to addressing global health challenges and enhancing the well-being of people worldwide.
Frequently Asked Questions
What is ACG's recent investment announcement?
ACG has announced a $200 million investment to establish its first capsule manufacturing operations in the United States, initially in Atlanta.
How many jobs will the new facility create?
ACG expects the new facility to create more than 200 jobs in the Atlanta area.
When will operations begin at the new facility?
Operations at the new facility are targeted to commence in early 2027.
What types of capsules will ACG manufacture in Atlanta?
ACG will manufacture both gelatin and vegetarian (HPMC) hard-shell capsules in the new facility.
How long has ACG been operating in North America?
ACG has been serving the North American market for over 25 years with a focus on integrating its operations and enhancing customer service.
